

**CREON® 10
MINIMICROSPHERES®
(Pancrelipase Delayed-release Capsules, USP)**

R_x only

500198 Rev Feb 2006

PRESCRIBING INFORMATION

DESCRIPTION

CREON® 10 Capsules are orally administered and contain pancrelipase (lipase 10,000 USP Units, protease 37,500 USP Units, and amylase 33,200 USP Units per capsule) which is of porcine pancreatic origin. Each CREON 10 Capsule is filled with 249 mg of delayed-release MINIMICROSPHERES®.

Inactive ingredients include dibutyl phthalate, dimethicone, hydroxypropylmethylcellulose phthalate, light mineral oil and polyethylene glycol. The capsule shells contain black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide. The capsule imprinting ink contains dimethicone, 2-ethoxyethanol, shellac, soya lecithin, and titanium dioxide.

CLINICAL PHARMACOLOGY

The pancreatic enzymes in CREON 10 Capsules are enteric-coated to resist gastric destruction or inactivation. The pancreatic enzymes catalyze the hydrolysis of fats to glycerol and fatty acids, protein into proteoses and derived substances and starch into dextrans and short chain sugars.

INDICATIONS

CREON 10 Capsules are indicated for patients with pancreatic exocrine insufficiency as is often associated with:

- cystic fibrosis
- chronic pancreatitis
- post-pancreatectomy
- post-gastrointestinal bypass surgery (e.g., Billroth II gastroenterostomy)
- ductal obstruction from neoplasm (e.g., of the pancreas or common bile duct)

CONTRAINDICATIONS

CREON 10 Capsules are contraindicated in the early stages of acute pancreatitis or in patients who are known to be hypersensitive to pork protein.

WARNINGS

Should symptoms of hypersensitivity appear, discontinue medication and initiate symptomatic and supportive therapy if necessary.

Strictures in the ileo-cecal region and/or ascending colon have been reported in cystic fibrosis patients treated with high doses of high-potency pancreatic enzyme supplements containing 20,000 or greater USP units of lipase per capsule. The underlying mechanism is unknown, but

42 caution should be exercised when doses in excess of 6,000 USP units lipase per kg per meal fail
43 to resolve symptoms, especially in patients with a history of intestinal complications such as
44 meconium ileus equivalent, short bowel syndrome, surgery or Crohn's disease. If symptoms
45 suggestive of gastrointestinal obstruction occur, the possibility of bowel stricture should be
46 investigated including evaluation of pancreatic enzyme therapy.

47

48 **PRECAUTIONS**

49 CREON 10 Capsules MINIMICROSPHERES SHOULD NOT BE CRUSHED OR CHEWED or
50 placed on foods having a pH greater than 5.5. These can dissolve the protective enteric coating
51 resulting in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity.

52

53 **Information for Patients**

54 CREON 10 Capsules are a pancreatic enzyme product prescribed to promote improved digestion
55 of foods, especially fat. The prescribed dosage should be taken with each meal and snack or as
56 directed by the physician. The capsules can be swallowed whole, or the contents poured on soft,
57 bland food. Care should be taken to avoid chewing or crushing of the capsule contents, which
58 can result in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity.
59 Patients should maintain adequate fluid intake. The prescribed dose range should not be
60 exceeded without calling your doctor.

61

62 The most common adverse reactions involve the stomach and intestine including diarrhea,
63 nausea, vomiting, bloating, constipation, stomach cramps or pain. If these symptoms are
64 persistent, contact your doctor.

65

66 **Carcinogenesis, Mutagenesis, Impairment of Fertility**

67 Long-term studies in animals have not been performed to evaluate carcinogenic potential.

68

69 **Pregnancy, Category C**

70 Animal reproduction studies have not been conducted with pancrelipase. It is also not known
71 whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect
72 reproduction capacity. CREON 10 Capsules should be given to a pregnant woman only if clearly
73 needed.

74

75 **Nursing Mothers**

76 It is not known whether this drug is excreted in human milk. Because many drugs are excreted in
77 human milk, caution should be exercised when CREON 10 Capsules are administered to a
78 nursing mother.

79

80 **ADVERSE REACTIONS**

81 The most frequently reported adverse reactions to pancreatic enzyme-containing products are
82 gastrointestinal in nature which may include nausea, vomiting, bloating, cramping, constipation
83 or diarrhea. Less frequently, allergic-type reactions have also been observed. Very high doses of
84 pancreatin have been associated with hyperuricosuria and hyperuricemia.

85

86 DOSAGE AND ADMINISTRATION

87 Clinical experience should dictate initial starting dose. Doses should be taken during meals or
88 snacks, not before or after. Do not take without food.

89

90 Adults and Children Over 6 Years Old

91 Usual initial starting dosage is one to two CREON 10 Capsules per meal or snack.

92

93 Children Under 6 Years Old

94 Usual initial starting dosage is up to one CREON 10 Capsule per meal or snack.

95

96 For cystic fibrosis patients, typical doses are 1,500 - 3,000 USP lipase units/kg/meal. Dosage
97 should be adjusted according to the severity of the disease, control of steatorrhea and
98 maintenance of good nutritional status. Doses in excess of 6,000 USP lipase units/kg/meal are
99 not recommended.

100

101 Dose increases, if required, should occur with careful monitoring of body weight and stool fat
102 content. When changing strengths of pancreatic enzyme products, care should be taken to
103 maintain equivalent lipase units for each divided dosage.

104

105 It is important to ensure adequate hydration of patients at all times while taking pancreatic
106 enzymes.

107

108 Where swallowing of capsules is difficult, the capsules may be carefully opened and the
109 MINIMICROSPHERES added to a small amount of soft food, with a pH less than 5.5. The soft
110 food should be swallowed immediately without chewing and followed with a glass of water or
111 juice to insure swallowing.

112

113 HOW SUPPLIED

114 CREON 10 MINIMICROSPHERES (Pancrelipase Delayed-release Capsules, USP) are available
115 in a two-piece gelatin capsule (brown opaque top half, natural transparent bottom half) imprinted
116 in white with "SOLVAY" and "1210". Each capsule contains tan-colored delayed-release
117 MINIMICROSPHERES of pancrelipase supplied in bottles of:

118

119 100.....NDC 0032-1210-01

120 250.....NDC 0032-1210-07

121

122 CREON 10 Capsules must be stored at 25 °C (77 °F); excursions permitted to 15 °-30 °C (59 °-
123 86 °F). [See USP Controlled Room Temperature.] PROTECT FROM MOISTURE. DO NOT
124 REFRIGERATE. Dispense in tight, light-resistant containers. For human consumption only.

125

126 **Manufactured By:**

127 Solvay Pharmaceuticals GmbH

128 Hannover, Germany

129

130 **Marketed by:**
131 **Solvay**
132 **Pharmaceuticals, Inc.**
133 Marietta, GA 30062
134
135 500198 Rev Feb 2006
136
137 MINIMICROSPHERES is
138 a registered Trademark of
139 Solvay Pharmaceuticals, Inc.
140
141 © 2006 Solvay Pharmaceuticals, Inc.